vs
Aclaris Therapeutics, Inc.（ACRS）与武田制药（TAK）财务数据对比。点击上方公司名可切换其他公司
武田制药的季度营收约是Aclaris Therapeutics, Inc.的3.3倍（$4.3M vs $1.3M）。武田制药净利率更高（3.4% vs -1528.6%，领先1532.0%）
Aclaris Therapeutics是一家处于临床阶段的生物制药企业，专注于研发针对免疫疾病、炎症性疾病和皮肤病的创新靶向疗法，核心管线覆盖斑秃、白癜风等未满足临床需求领域，致力于为全球相关患者提供新型治疗选择。
武田制药是总部位于日本的跨国制药企业，为亚洲第三大制药公司，全球营收排名位列前二十。集团全球员工超4.95万人，核心业务聚焦肿瘤、罕见病、神经科学、消化疾病及血浆衍生疗法等领域。
ACRS vs TAK — 直观对比
营收规模更大
TAK
是对方的3.3倍
$1.3M
净利率更高
TAK
高出1532.0%
-1528.6%
损益表 — Q4 2025 vs Q1 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3M | $4.3M |
| 净利润 | $-19.8M | $144.2K |
| 毛利率 | 58.9% | 66.5% |
| 营业利润率 | -1755.5% | 5.0% |
| 净利率 | -1528.6% | 3.4% |
| 营收同比 | -85.9% | — |
| 净利润同比 | 79.5% | — |
| 每股收益（稀释后） | $-0.16 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACRSTAK
| Q4 25 | $1.3M | — | ||
| Q3 25 | $3.3M | — | ||
| Q2 25 | $1.8M | $4.3M | ||
| Q1 25 | $1.5M | — | ||
| Q4 24 | $9.2M | — | ||
| Q3 24 | $4.3M | — | ||
| Q2 24 | $2.8M | — | ||
| Q1 24 | $2.4M | $4.0M |
净利润ACRSTAK
| Q4 25 | $-19.8M | — | ||
| Q3 25 | $-14.6M | — | ||
| Q2 25 | $-15.4M | $144.2K | ||
| Q1 25 | $-15.1M | — | ||
| Q4 24 | $-96.6M | — | ||
| Q3 24 | $-7.6M | — | ||
| Q2 24 | $-11.0M | — | ||
| Q1 24 | $-16.9M | $317.0K |
毛利率ACRSTAK
| Q4 25 | 58.9% | — | ||
| Q3 25 | 83.7% | — | ||
| Q2 25 | 71.0% | 66.5% | ||
| Q1 25 | 65.2% | — | ||
| Q4 24 | 92.3% | — | ||
| Q3 24 | 85.0% | — | ||
| Q2 24 | 77.4% | — | ||
| Q1 24 | 66.3% | 69.1% |
营业利润率ACRSTAK
| Q4 25 | -1755.5% | — | ||
| Q3 25 | -519.8% | — | ||
| Q2 25 | -1035.9% | 5.0% | ||
| Q1 25 | -1242.9% | — | ||
| Q4 24 | -1082.3% | — | ||
| Q3 24 | -240.9% | — | ||
| Q2 24 | -464.7% | — | ||
| Q1 24 | -789.4% | 12.2% |
净利率ACRSTAK
| Q4 25 | -1528.6% | — | ||
| Q3 25 | -443.0% | — | ||
| Q2 25 | -868.3% | 3.4% | ||
| Q1 25 | -1036.8% | — | ||
| Q4 24 | -1048.3% | — | ||
| Q3 24 | -174.6% | — | ||
| Q2 24 | -397.2% | — | ||
| Q1 24 | -706.5% | 7.9% |
每股收益（稀释后）ACRSTAK
| Q4 25 | $-0.16 | — | ||
| Q3 25 | $-0.12 | — | ||
| Q2 25 | $-0.13 | — | ||
| Q1 25 | $-0.12 | — | ||
| Q4 24 | $-1.21 | — | ||
| Q3 24 | $-0.11 | — | ||
| Q2 24 | $-0.15 | — | ||
| Q1 24 | $-0.24 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $20.0M | $2.5B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $103.1M | $45.1B |
| 总资产 | $160.5M | $92.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACRSTAK
| Q4 25 | $20.0M | — | ||
| Q3 25 | $25.3M | — | ||
| Q2 25 | $25.4M | $2.5B | ||
| Q1 25 | $30.4M | — | ||
| Q4 24 | $24.6M | — | ||
| Q3 24 | $47.7M | — | ||
| Q2 24 | $22.8M | — | ||
| Q1 24 | $35.8M | $3.0B |
股东权益ACRSTAK
| Q4 25 | $103.1M | — | ||
| Q3 25 | $120.1M | — | ||
| Q2 25 | $131.7M | $45.1B | ||
| Q1 25 | $144.1M | — | ||
| Q4 24 | $155.6M | — | ||
| Q3 24 | $130.2M | — | ||
| Q2 24 | $133.8M | — | ||
| Q1 24 | $142.0M | $47.3B |
总资产ACRSTAK
| Q4 25 | $160.5M | — | ||
| Q3 25 | $175.5M | — | ||
| Q2 25 | $189.1M | $92.6B | ||
| Q1 25 | $198.1M | — | ||
| Q4 24 | $220.3M | — | ||
| Q3 24 | $182.4M | — | ||
| Q2 24 | $161.1M | — | ||
| Q1 24 | $174.1M | $98.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-13.1M | — |
| 自由现金流经营现金流 - 资本支出 | $-13.2M | — |
| 自由现金流率自由现金流/营收 | -1015.8% | — |
| 资本支出强度资本支出/营收 | 1.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-47.2M | — |
8季度趋势，按日历期对齐
经营现金流ACRSTAK
| Q4 25 | $-13.1M | — | ||
| Q3 25 | $-10.9M | — | ||
| Q2 25 | $-10.0M | — | ||
| Q1 25 | $-13.1M | — | ||
| Q4 24 | $-8.9M | — | ||
| Q3 24 | $22.0M | — | ||
| Q2 24 | $-12.3M | — | ||
| Q1 24 | $-20.8M | — |
自由现金流ACRSTAK
| Q4 25 | $-13.2M | — | ||
| Q3 25 | $-11.0M | — | ||
| Q2 25 | $-10.0M | — | ||
| Q1 25 | $-13.1M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-12.3M | — | ||
| Q1 24 | $-20.9M | — |
自由现金流率ACRSTAK
| Q4 25 | -1015.8% | — | ||
| Q3 25 | -332.1% | — | ||
| Q2 25 | -563.5% | — | ||
| Q1 25 | -900.3% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -446.0% | — | ||
| Q1 24 | -873.6% | — |
资本支出强度ACRSTAK
| Q4 25 | 1.9% | — | ||
| Q3 25 | 0.7% | — | ||
| Q2 25 | 1.2% | — | ||
| Q1 25 | 3.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.5% | — | ||
| Q1 24 | 5.6% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
